Related content

Histone Deacetylase Inhibitors and Colorectal Cancer: what is new?

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 14, Iss. 9, 2014-11 ,pp. : 1220-1227

Bentham Science Publishers

Access to resources Recommend Favorite

Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing’s sarcoma cells

By Sonnemann Jürgen   Dreyer Linn   Hartwig Maite   Palani Chithra   Hong Le   Klier Ulrike   Bröker Barbara   Völker Uwe   Beck James  

Journal of Cancer Research and Clinical Oncology, Vol. 133, Iss. 11, 2007-11 ,pp. : 847-858

Springer Publishing Company

Access to resources Recommend Favorite

Superior antimitogenic and chemosensitization activities of the combination treatment of the histone deacetylase inhibitor apicidin and proteasome inhibitors on human colorectal cancer cells

By      

International Journal of Oncology, Vol. 44, Iss. 1, 2014-01 ,pp. : 105-128

Spandidos Publications

Access to resources Recommend Favorite

Genome-wide identification of TCF7L2/TCF4 target miRNAs reveals a role for miR-21 in Wnt-driven epithelial cancer

By                

International Journal of Oncology, Vol. 40, Iss. 2, 2012-01 ,pp. : 519-526

Spandidos Publications

Access to resources Recommend Favorite

Susceptibility of hepatoma-derived cells to histone deacetylase inhibitors is associated with ID2 expression

By        

International Journal of Oncology, Vol. 42, Iss. 4, 2013-01 ,pp. : 1159-1166

Spandidos Publications

Access to resources Recommend Favorite